Skip to main content
. 2019 May 9;5(8):1124–1131. doi: 10.1001/jamaoncol.2019.0528

Figure 3. Association of Circulating Tumor DNA (ctDNA) Analysis With Early Detection of Relapse and Detection of Clinical Actionable Mutations.

Figure 3.

A, Comparison of time to relapse by ctDNA and standard-of-care computed tomography (CT). The mean time from surgery to relapse detection was 5.5 months (range, 0.4-17.7 months) for ctDNA and 14.2 months (range, 5.9-31.1 months for CT). Dashed lines indicate mean time in months of recurrence based on CT and ctDNA. B, For all patients with relapsing disease, the ctDNA levels in plasma increased over time from ctDNA detection to radiologic response. Early time points before and during adjuvant chemotherapy were omitted. Each colored curve represents data from a different patient. C, Fraction of recurrence in ctDNA-positive patients with actionable mutations detected in plasma. D, The actionable variants occurred with variant allele frequencies (VAFs) similar to the nonactionable variants. Association between the mean ctDNA VAF and the VAF of the actionable mutations is shown.